Lotus Pharmaceutical Co., Ltd. has announced that VAZKEPA® (icosapent ethyl) has received approval from Singapore’s Health Sciences Authority (HSA), marking the company’s first Southeast Asian market authorisation for the product.

• Regulatory approval: VAZKEPA® (icosapent ethyl) is approved as an adjunct to maximally tolerated statin therapy to reduce the risk of cardiovascular events in adult patients with elevated triglycerides and high cardiovascular risk, including established cardiovascular disease or diabetes with additional risk factors.
• Regulatory date: Singapore’s HSA granted approval in December 2025, and the registration appears on the list of recent new drug approvals published by the HSA.
• Clinical context: The approval addresses a patient population at elevated risk of cardiovascular disease, a leading cause of mortality locally, with significant prevalence of hyperlipidaemia and hypertension reported in national health data.

This summary is based on a press release issued by Lotus Pharmaceutical Co., Ltd.